Considering the pivotal role of cholesterol and mevalonate in cancer progression, particularly in promoting a high proliferation rate and metabolic shifting, as well as contributing to drug resistance via the stimulation of the estrogen-related receptor alpha (ERRα) pathway [37], it is imperative to explore their involvement in cancer drug resistance. Here, ESRRA is linked to cancer.